Get the Stockscreener App
6.89
2.89%
-0.205
After Hours:
6.88
-0.010
-0.15%
Passage Bio Inc stock is traded at $6.89, with a volume of 9,472.
It is down -2.89% in the last 24 hours and down -20.44% over the past month.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.
See More
Previous Close:
$7.095
Open:
$7.02
24h Volume:
9,472
Relative Volume:
0.17
Market Cap:
$22.10M
Revenue:
-
Net Income/Loss:
$-45.52M
P/E Ratio:
-0.7084
EPS:
-9.7265
Net Cash Flow:
$-31.51M
1W Performance:
-6.64%
1M Performance:
-20.44%
6M Performance:
-13.88%
1Y Performance:
+1,398%
1-Day Range:
$6.88
$7.265
1-Week Range:
$6.61
$7.88
52-Week Range:
$0.257
$20.00
Passage Bio Inc Stock (PASG) Company Profile
Name
Passage Bio Inc
Sector
Industry
Phone
(267) 866-0312
Address
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Compare PASG vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PASG
Passage Bio Inc
|
6.89 | 22.76M | 0 | -45.52M | -31.51M | -9.7265 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-10-26 | Resumed | Chardan Capital Markets | Buy |
| Nov-29-24 | Resumed | Wedbush | Outperform |
| Sep-03-24 | Initiated | Rodman & Renshaw | Buy |
| Mar-08-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-19-22 | Downgrade | Goldman | Buy → Neutral |
| Jul-01-21 | Initiated | Raymond James | Outperform |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Mar-04-21 | Upgrade | Goldman | Neutral → Buy |
| Feb-04-21 | Initiated | Guggenheim | Buy |
| Jan-25-21 | Initiated | Wedbush | Outperform |
| Jan-04-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-11-20 | Initiated | Citigroup | Neutral |
| Aug-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-25-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-25-20 | Initiated | Chardan Capital Markets | Buy |
| Mar-24-20 | Initiated | Cowen | Outperform |
| Mar-24-20 | Initiated | Goldman | Buy |
| Mar-24-20 | Initiated | JP Morgan | Overweight |
View All
Passage Bio Inc Stock (PASG) Latest News
Umoja Biopharma Appoints Dr. Marcela Maus and Dr. Athena Countouriotis to Board of Directors - The Manila Times
MRKR PE Ratio & Valuation, Is MRKR Overvalued - Intellectia AI
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Passage BIO (PASG) CFO receives stock option grant for 15,610 shares - Stock Titan
Passage BIO (PASG) CEO receives 58,000-share stock option grant - Stock Titan
PASG Surges 13% on Thin Volume — But No Catalyst to Back It - Bitget
Passage Bio (PASG) price target increased by 21.85% to 40.39 - MSN
Buybacks Report: Can Passage Bio Inc stock outperform in a bear market2026 Setups & Reliable Breakout Forecasts - baoquankhu1.vn
Passage Bio Inc Stock (ISIN: US70267E1055) Faces Biotech Headwinds Amid Analyst Optimism and Funding - AD HOC NEWS
Can Passage Bio Inc stock outperform in a bear market2026 Buyback Activity & Daily Entry Point Alerts - baoquankhu1.vn
Passage Bio Ends Hopewell Lab Lease, Extends Cash Runway - The Globe and Mail
Passage Bio (PASG) pays $4.8M to end long-term Hopewell lab lease - Stock Titan
Passage Bio Advances Frontotemporal Dementia Trial and Reports 2025 Results - MyChesCo
Weekly Trades: Is DISTW stock a hidden gemMarket Risk Report & Safe Capital Growth Plans - baoquankhu1.vn
Passage Bio (NASDAQ:PASG) Lowered to Sell Rating by Wall Street Zen - Defense World
Will SBLK stock keep outperforming rivalsPortfolio Value Summary & AI Driven Price Forecasts - Naître et grandir
Portfolio Shifts: Does PRLD have declining or rising EPSTrade Signal Summary & Weekly Top Performers Watchlists - baoquankhu1.vn
Trade Report: What insider trading reveals about Passage Bio Inc. stockPortfolio Profit Report & Precise Entry and Exit Recommendations - Naître et grandir
Passage Bio (PASG) Gets a Buy from Chardan Capital - The Globe and Mail
PASG: Gene therapy for FTD-GRN advances with early-stage focus, strong biomarker data, and regulatory planning - TradingView
PASG: Gene therapy for FTD-GRN advances with safer dosing, strong biomarker data, and regulatory engagement - TradingView
Passage Bio (PASG) Analyst Rating: Canaccord Genuity Lowers Pric - GuruFocus
Analysts Are Bullish on These Healthcare Stocks: Esperion (ESPR), Passage Bio (PASG) - The Globe and Mail
Passage Bio FY Income from Operations USD -49.296 Million - marketscreener.com
PASG Reports Drop in Cash Reserves for 2025 - GuruFocus
Passage Bio Reports 2025 Results, Advances FTD Program - TipRanks
Passage Bio is actively advancing its differentiated preclinical research project for Huntington's disease. - Bitget
Passage BIO 10-K: Net loss $45.5M; EPS $(14.35) - TradingView
PASG: Net loss narrowed to $45.5M in 2025 as PBFT02 advanced and cash runway extended to Q1 2027 - TradingView
Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights - Bitget
Passage Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Passage Bio (NASDAQ: PASG) shows strong PBFT02 biomarker gains in FTD - Stock Titan
Passage Bio's 2025 net loss narrows - TradingView
PASG: Clinical progress in FTD and Huntington's, improved financials, and cash runway to 1Q 2027 - TradingView
Passage Bio (NASDAQ: PASG) narrows 2025 loss and advances PBFT02 trial - Stock Titan
PASG Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
PASG Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Passage Bio Inc expected to post a loss of $2.57 a shareEarnings Preview - TradingView
PASG: Gene therapy for FTD-GRN demonstrates strong biomarker response and safety, with key data due in 2024 - TradingView
Passage Bio management to present at two healthcare conferences - MSN
Passage Bio Management to Present at Two Healthcare Conferences - MyChesCo
Recap Report: Can Passage Bio Inc ride the EV waveQuarterly Risk Review & Safe Entry Point Identification - baoquankhu1.vn
Moving Averages: What is the earnings history of Passage Bio Inc2025 Analyst Calls & Risk Managed Investment Entry Signals - baoquankhu1.vn
Nasdaq Moves: Can Passage Bio Inc. reach all time highs this yearBear Alert & Expert Approved Trade Ideas - mfd.ru
Can Passage Bio Inc. stock hit record highs againInsider Buying & Advanced Technical Analysis Signals - mfd.ru
Passage Bio to Participate in Upcoming Investor Conferences - Caledonian Record
What downside risks could hit Goldman Sachs Equal Weight U.S. stockJuly 2025 Catalysts & Accurate Entry/Exit Alerts - mfd.ru
Can Passage Bio Inc. outperform in the next rallyJuly 2025 Opening Moves & Free Daily Entry Point Trade Alerts - mfd.ru
Will BioMarin Pharmaceutical Inc. (BM8) stock maintain strong growth2025 Earnings Impact & Weekly Chart Analysis and Guides - mfd.ru
Is Passage Bio Inc.’s ROIC above industry averageJuly 2025 Rallies & Entry Point Strategy Guides - mfd.ru
Why Putnam ETF Trust Putnam BioRevolution stock appeals to dividend investorsMarket Volume Summary & Low Risk Growth Stock Ideas - mfd.ru
Passage Bio Inc Stock (PASG) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):